International Journal of Laboratory Hematology最新文献

{"title":"Supplement Article","authors":"","doi":"10.1111/ijlh.14436","DOIUrl":"https://doi.org/10.1111/ijlh.14436","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 S1","pages":"3-34"},"PeriodicalIF":2.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Moving Average for Continuous Real-Time QC; Real-World Application Illustrated","authors":"Huub H. van Rossum, Jean-Marc Giannoli, Tony Badrick","doi":"10.1111/ijlh.14462","DOIUrl":"10.1111/ijlh.14462","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"570-573"},"PeriodicalIF":2.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline Variants in Idiopathic Erythrocytosis Identified by Multigene Panel Sequencing","authors":"Min-Seung Park, Boram Kim, Hyun-Young Kim, Chul Won Jung, Jun Ho Jang, Hee-Jin Kim","doi":"10.1111/ijlh.14458","DOIUrl":"10.1111/ijlh.14458","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"563-566"},"PeriodicalIF":2.2,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143660185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Abnormal Scattergram of Peripheral Blood Leukocytes Indicative of the Presence of Monoclonal IgM Immunoglobulins","authors":"Michela Pelloso, Paola Galozzi, Francesca Tosato, Paolo Zaupa, Sara Altinier, Giulia Musso, Daniela Basso, Martina Montagnana","doi":"10.1111/ijlh.14463","DOIUrl":"10.1111/ijlh.14463","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"567-569"},"PeriodicalIF":2.2,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cold Stored Platelets: A Solution for Platelet Aggregation External Quality Assessment/Proficiency Testing","authors":"Christopher Reilly-Stitt,&nbsp;Ian Jennings,&nbsp;Steve Kitchen,&nbsp;Michael Cahillane,&nbsp;Christine Saunders,&nbsp;Chloe George,&nbsp;Tom Scorer,&nbsp;Isobel D. Walker","doi":"10.1111/ijlh.14445","DOIUrl":"10.1111/ijlh.14445","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To achieve accreditation for ISO 15189, laboratories are required to either participate in EQA exercises or intra-laboratory comparisons to meet the standard. Light transmission aggregometry performed by laboratory scientists for the clinical investigation of possible platelet function defects is time dependent. Current EQA available audits the interpretation of platelet aggregation traces.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Could NEQAS BC provide external quality assessment (EQA) material to centres employing Light Transmission Aggregometry LTA for clinical investigation of platelet function? The use of fresh donor platelets could audit more of the analytical and post analytical aspects of light transmission aggregation than currently available.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A pool of donor platelets was split into aliquots that were distributed to testing centres across England, Scotland and Wales for testing within a 72 h window. Participating centres employed their locally validated testing methods for LTA assays, for agonists including ADP; Arachidonic acid; Collagen; Epinephrine; Ristocetin; TRAP and U46619.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Five different aggregation platforms were used including: Chronolog 700; Helena Aggram; PAP-8; Stago TA-8V and Sysmex CN-series. Sample packs were tested through the 72 h window with most sites performing LTA on the EQA material on day one of the three.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The % consensus of interpretations provided by participants for agonists including: ADP; Arachidonic acid; Collagen; Epinephrine and Ristocetin ranged from 94% to 100% indicating that the material is stable plus centres using different aggregometers returned the same clinical interpretations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"529-535"},"PeriodicalIF":2.2,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ITGAM Upregulation in Acute Myeloid Leukemia Leads to Poor Prognosis Associated With Infiltration of Inhibitory Innate Immune Cells","authors":"Chen-Chen Qin,&nbsp;Xiu-Zhen Tong,&nbsp;Chang Su,&nbsp;Zhen-Hai Zhou,&nbsp;Dong Zheng","doi":"10.1111/ijlh.14444","DOIUrl":"10.1111/ijlh.14444","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute myeloid leukemia (AML) is a prevalent and potentially fatal hematologic malignancy with limited improvements in survival rates over the past few decades. ITGAM, encoding CD11b, is a significant integrin component in leukocytes, involved in various biological processes. However, its role in AML prognosis and immune cell infiltration remains poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study investigated the prognostic significance and potential function of ITGAM in AML using comprehensive bioinformatic analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>ITGAM expression was markedly upregulated in AML patients, correlating with advanced age (&gt; 60 years), French-American-British (FAB) classification subtypes M4 and M5, and intermediate or poor cytogenetic risk. Gene enrichment analysis revealed that ITGAM was involved in immune system regulation and was positively associated with the infiltration of neutrophils, immature dendritic cells, and macrophages in AML. Notably, the expression of ITGAM was linked to increased infiltration of immunosuppressive subsets of these innate immune cells, which may partially explain its association with a poorer prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings suggest that ITGAM could serve as a valuable prognostic biomarker in AML, reflecting an adverse prognosis associated with enhanced infiltration of immunosuppressive innate immune cells.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"481-490"},"PeriodicalIF":2.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How I Investigate Measurable Residual Disease in B-Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi-Specific Monoclonal Antibodies and 19CAR-T Cells","authors":"Maura Rosane Valerio Ikoma-Colturato,&nbsp;Felipe Magalhães Furtado,&nbsp;Elen de Oliveira,&nbsp;Fabiola Gevert,&nbsp;Roberia Mendonça,&nbsp;The Brazilian Society of Bone Marrow and Cell Therapy (SBTMO) MRD Working Group","doi":"10.1111/ijlh.14448","DOIUrl":"10.1111/ijlh.14448","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Measurable residual disease (MRD) in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) following anti-CD19 targeted therapies requires specific strategies to identify residual blast cells due to loss or reduced CD19 expression that makes it inconsistent as a primitive marker for B-cell gating.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Due to the increased access of BCP-ALL patients to therapies with CD3/CD19 bispecific T-cell engagers (BiTe) and CD19-targeted chimeric antigen receptor T-Cell (CAR-T), it is essential that flow cytometry laboratories are prepared to evaluate therapeutic responses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>Here, validated strategies for MRD detection in the context of anti-CD19 therapies are described, accessible to flow cytometry laboratories according to their different facilities. The paper includes an 8-color flow cytometry (FC) strategy for BCP-ALL MRD based on alternative gating without the use of additional markers (Euroflow protocol), as well as other strategies using alternative markers to CD19, comprising 2 protocols using 8 colors, one using 10 colors and another 14 colors/15 markers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Different strategies are needed to detect MRD without using CD19 for B-cell population gating after CD19-targeted therapies. However, it is essential that validated protocols are used according to the available resources to ensure reliable results for clinical decision-making.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"398-406"},"PeriodicalIF":2.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14448","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Diversity in KMT2A-r and KMT2A-Wt Groups: Assessing the Prognostic Value of Markers in BCP-ALL Among Infants","authors":"Karina Ilyasova,&nbsp;Elena Zerkalenkova,&nbsp;Olga Soldatkina,&nbsp;Anna Kazakova,&nbsp;Natalya Myakova,&nbsp;Julia Roumiantseva,&nbsp;Veronica Fomynih,&nbsp;Alexander Popov,&nbsp;Grigory Tsaur,&nbsp;Yulia Olshanskaya,&nbsp;Michael Maschan","doi":"10.1111/ijlh.14442","DOIUrl":"10.1111/ijlh.14442","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Infant BCP-ALL is classified into <i>KMT2A</i>-r and <i>KMT2A</i>-wt groups, both showing heterogeneity. <i>KMT2A</i> rearrangements indicate poor prognosis, but outcomes vary by fusion partner. The <i>KMT2A</i>-wt group includes cases in the B-other ALL subgroup, with unclear prognostic significance. We aim to improve understanding of molecular subtypes in <i>KMT2A</i>-r and <i>KMT2A</i>-wt, focusing on <i>NUTM1</i> and <i>PAX5</i> rearrangements.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We analyzed 175 infants (aged 0–365 days) diagnosed with BCP-ALL from 2010 to 2023 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Genomic aberrations were identified by karyotyping, FISH and RNA-seq. RNA-seq was performed using the Illumina, and gene fusions were validated by Sanger sequencing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There was no difference in survival based on <i>KMT2A</i> partner genes. The <i>KMT2A::AFF1</i> group showed similar outcomes to other partners, with 2-year EFS of 36% (95% CI, 21%–59%) versus 37% (95% CI, 23%–60%) (log-rank test, <i>p</i> = 0.9). In the <i>KMT2A</i>-wt group (<i>n</i> = 33, 17.7% of cases), <i>NUTM1-r</i> (<i>n</i> = 9) and <i>PAX5-r</i> (<i>n</i> = 10) accounted for 27% and 30.3%, respectively. The <i>NUTM1</i>-r and <i>PAX5</i>-r groups showed excellent survival rates, with 2-year EFS of 80% (95% CI, 52%–100%) and 100% (95% CI, 100%–100%), respectively, but the small cohort size limit the statistical power of the analysis (log-rank test, <i>p</i> = 0.9).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Survival in the <i>KMT2A</i>-r group did not differ by fusion partner. <i>NUTM1</i> rearrangements showed a favorable prognosis, and <i>PAX5</i>-rearranged patients had better outcomes than previously reported. In the <i>NUTM1</i>-r group, the most common fusion, <i>BRD9:NUTM1</i>, showed variability in breakpoints (Exons 3, 8, and 14 of <i>BRD9</i>).</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"472-480"},"PeriodicalIF":2.2,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Chemoimmunotherapy","authors":"Yara Mohamed Ahmed,&nbsp;Nashwa El-Khazragy,&nbsp;Riham Abdel-Hamid Haroun,&nbsp;Shadia Abdel-Hamid Fathy","doi":"10.1111/ijlh.14440","DOIUrl":"10.1111/ijlh.14440","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Long noncoding RNAs (lncRNAs) have emerged as key regulators of cancer; in addition, they have been identified as novel therapeutic targets and biomarkers for several cancers, including diffuse large B-cell lymphoma (DLBCL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 75 DLBCL patients and 30 control subjects with active lymph nodes were enrolled into our study. The baseline expression levels of lncRNAs HOTAIR, MALAT1, and PANDA in paraffin-embedded blocks of lymph nodes from DLBCL patients and controls were evaluated using reverse transcription quantitative real-time PCR (RTqPCR) technique.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The expression levels of HOTAIR and MALAT1 were increased while PANDA expression level was decreased in DLBCL patients when compared to controls and in R-CHOP-resistant patients when compared to responder ones. Also, HOTAIR, MALAT1, and PANDA baseline expression levels were significantly correlated with the different clinical parameters in this study. As diagnostic and prognostic tools, the results obtained from the ROC curve revealed that the PANDA baseline expression level was the best one as the diagnostic biomarker could differentiate DLBCL disease and the prognostic biomarker predicts R-CHOP resistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, the integrated approach reveals that lncRNAs HOTAIR and MALAT1 were upregulated, while lncRNA PANDA was downregulated in DLBCL patients compared with controls, and the three lncRNAs closely associated with clinical prognosis. This study warrants future studies in clinical trials for the treatment of R-CHOP-resistant DLBCL patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"463-471"},"PeriodicalIF":2.2,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening","authors":"Mazen Assar,&nbsp;Henning Nilius,&nbsp;Natalie Kearn,&nbsp;Wilma Hopman,&nbsp;Michael Nagler,&nbsp;Maha Othman","doi":"10.1111/ijlh.14443","DOIUrl":"10.1111/ijlh.14443","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Thrombophilia, a blood coagulation disorder, poses risks of venous thromboembolism (VTE). Coagulation assays may not be sufficient to assess VTE risk and global assays such as Rotational Thromboelastometry (ROTEM) may add valuable information. We investigated ROTEM's capacity to detect hypercoagulability in patients undergoing thrombophilia screening, its potential impact on patient outcomes, and limitations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Comprehensive clinical, laboratory, genetic tests, and ROTEM (EXTEM and INTEM) were conducted for 356 patients referred for thrombophilia screening at an academic hospital outpatient unit. Hypercoagulability was identified as a shorter clot formation time (CFT), larger alpha angle (AA), and greater maximum clot firmness (MCF), and was compared in patients with and without VTE. Statistically this was analyzed using Mann–Whitney <i>U</i> and Chi-square tests with <i>p</i> &lt; 0.05 considered significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 356 patients, 64.6% had previous VTE, with 76.9% experiencing one event, 14.3% recurrent (35.6% unprovoked, 64.4% provoked). 22.5% of patients were on anticoagulation. Those with VTE history exhibited significant alterations in EXTEM and INTEM parameters compared to those without (<i>p</i> &lt; 0.001), showing decreased CFT and increased AA and MCF. However, receiver operating characteristic curves for these variables indicated that none were able to discriminate between those individuals with and without thromboembolic complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ROTEM does not appear to be a strong discriminatory test. However, it can detect hypercoagulopathy in patients referred for thrombophilia screening. Abnormal ROTEM may indicate a higher risk for recurrence. However, this can only be determined in prospective cohort studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 3","pages":"520-528"},"PeriodicalIF":2.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14443","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}